Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of the ATG4-LC3 pathway suppressed osteoclast maturation.
Hiura F, Kawabata Y, Aoki T, Mizokami A, Jimi E. Hiura F, et al. Among authors: aoki t. Biochem Biophys Res Commun. 2022 Dec 3;632:40-47. doi: 10.1016/j.bbrc.2022.09.065. Epub 2022 Sep 20. Biochem Biophys Res Commun. 2022. PMID: 36198202 Free article.
Luteolin Is a Potential Immunomodulating Natural Compound against Pulpal Inflammation.
Kawakami K, Fukuda T, Toyoda M, Nakao Y, Hayashi C, Watanabe Y, Aoki T, Shinjo T, Iwashita M, Yamashita A, Shida M, Sanui T, Uchiumi T, Nishimura F. Kawakami K, et al. Among authors: aoki t. Biomed Res Int. 2024 Jan 25;2024:8864513. doi: 10.1155/2024/8864513. eCollection 2024. Biomed Res Int. 2024. PMID: 38304347 Free PMC article.
Scaffold-free bone-like 3D structure established through osteogenic differentiation from human gingiva-derived stem cells.
Toyoda M, Fukuda T, Fujimoto R, Kawakami K, Hayashi C, Nakao Y, Watanabe Y, Aoki T, Shida M, Sanui T, Taguchi M, Yamamichi K, Okabe A, Okada T, Oka K, Nakayama K, Nishimura F, Kajioka S. Toyoda M, et al. Among authors: aoki t. Biochem Biophys Rep. 2024 Feb 15;38:101656. doi: 10.1016/j.bbrep.2024.101656. eCollection 2024 Jul. Biochem Biophys Rep. 2024. PMID: 38379857 Free PMC article.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: aoki t. Aliment Pharmacol Ther. 2024 May 8. doi: 10.1111/apt.18037. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38716823
A novel scoring system to predict short-term mortality after living donor liver transplantation for acute liver failure.
Shimata K, Yoon YI, Hibi T, Morinaga J, Narayanan AK, Toshima T, Ito T, Akamatsu N, Kotera Y, Hong SK, Hasegawa Y, Umeda Y, Reddy MS, Ong AL, Sivaprasadan S, Varghese J, Sugawara Y, Chen CL, Suh KS, Ikegami T, Lee KW, Lee SG; Vanguard Multicenter Study of iLDLT (International Living Donor Liver Transplantation) group; Sudhindran S, Yoshizumi T, Hatano E, Okumura S, Hasegawa K, Egawa H, Obara H, Yasui K, Ogura Y, Jobara K, Nitta H, Katagiri H, Otsuka M, Kuboki S, Eguchi S, Hara T, Eguchi H, Sasaki K, Aoki T, Ohdan H, Ohira M, Takada Y, Ogawa K, Fukumoto T, Kuramitsu K, Saiura A, Ichida H, Hashimoto T, Marubashi S, Sato N, Ushigome H, Harada S, Soejima Y, Masuda Y, Shimada M, Saitou Y, Taketomi A, Goto R, Shimamura T, Mizuno S, Tanemura A, Endo I, Unno M, Miyagi S, Okamura Y, Aramaki O, Hakamada K, Ishido K, Kato Y, Takahara T, Takatsuki M, Ono S. Shimata K, et al. Among authors: aoki t. Am J Transplant. 2024 Apr 29:S1600-6135(24)00288-0. doi: 10.1016/j.ajt.2024.04.016. Online ahead of print. Am J Transplant. 2024. PMID: 38692411 Free article.
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Persano M, et al. Among authors: aoki t. Target Oncol. 2024 Apr 30. doi: 10.1007/s11523-024-01061-0. Online ahead of print. Target Oncol. 2024. PMID: 38689194
4,406 results